Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials
ObjectiveTo systematically evaluate the efficacy and safety of a new hypoglycemic drug, tirzepatide, for treating obesity based on indicators such as BMI, waist circumference, and body weight.MethodsA search formula was written using search terms such as “tirzepatide,” “overweight,” and “obesity.” A...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2024.1277113/full |
| _version_ | 1797336050408882176 |
|---|---|
| author | Wenting Cai Wenting Cai Ruobin Zhang Ruobin Zhang Yao Yao Qiuhui Wu Jinping Zhang |
| author_facet | Wenting Cai Wenting Cai Ruobin Zhang Ruobin Zhang Yao Yao Qiuhui Wu Jinping Zhang |
| author_sort | Wenting Cai |
| collection | DOAJ |
| description | ObjectiveTo systematically evaluate the efficacy and safety of a new hypoglycemic drug, tirzepatide, for treating obesity based on indicators such as BMI, waist circumference, and body weight.MethodsA search formula was written using search terms such as “tirzepatide,” “overweight,” and “obesity.” A comprehensive search was conducted on databases such as PubMed, Cochrane Library, Embase, and Web of Science using a computer. Random controlled trial (RCT) literature was selected based on inclusion and exclusion criteria. After extracting the data, literature bias risk assessment and meta-analysis were conducted using RevMan 5.4 software. The search deadline is from the establishment of each database to May 2023.ResultsA total of 12 randomized controlled trials were included, with a total of 11,758 patients. Meta analysis results showed that compared with the glucagon like peptide-1 receptor agonist (GLP-1 RAs), placebo and insulin groups, tirzepatide could significantly reduce the BMI (body mass index) of patients [MD = −1.71, 95% CI (−2.46, −0.95), p < 0.00001], [MD = −3.99, 95% CI (−3.69, −2.45), p < 0.00001], [MD = −4.02, 95% CI (−4.72, −3.31), p < 00.00001]. In terms of decreasing waist circumference, tirzepatide has a more significant advantage [MD = −4.08, 95% CI (−5.77, −2.39), p < 0.00001], [MD = −7.71, 95% CI (−10.17, −5.25), p < 0.00001], [MD = −9.15, 95% CI (−10.02, −8.29), p < 0.00001]. In the analysis of body weight, tirzepatide showed a more significant reduction effect compared to the control group [MD = −5.65, 95% CI (−7.47, −3.82), p < 0.001], [MD = −10.06, 95% CI (−12.86, −7.25), p < 0.001], [MD = −10.63, 95% CI (−12.42, −8.84), p < 0.001]. In comparison with placebo, tirzepatide had a prominent advantage in weight loss ≥20% and ≥25% [RR = 30.43, 95% CI (19.56, 47.33), p < 0.00001], [RR = 37.25, 95% CI (26.03, 53.30), p < 0.00001]. Subgroup analysis showed a dose-dependent therapeutic effect. In terms of safety, compared with the placebo and insulin groups, the incidence of gastrointestinal adverse reactions was markedly higher in the tirzepatide group, slightly higher to the GLP-1 RAs group. The hypoglycemic (<70 mg/dL) risk of tirzepatide was slightly higher to that of placebo and GLP-1 RAs, but significantly lower than that of the insulin group [RR = 0.46, 95% CI (0.36, 0.58), p < 0.001]. The incidence of other adverse events, including pancreatitis, cholecystitis, major adverse cardiovascular events-4, hypersensitivity reactions, and neoplasms did not show significant statistical differences compared to the control group (p > 0.05).ConclusionTirzepatide, as a weight loss drug, significantly reduces BMI, waist circumference and body weight while gastrointestinal adverse reactions need to be vigilant. Overall, its efficacy is significant and its safety is high. |
| first_indexed | 2024-03-08T08:48:33Z |
| format | Article |
| id | doaj.art-9cb9de987c2f41c59064a184c2172fe3 |
| institution | Directory Open Access Journal |
| issn | 2296-2565 |
| language | English |
| last_indexed | 2024-03-08T08:48:33Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj.art-9cb9de987c2f41c59064a184c2172fe32024-02-01T14:23:48ZengFrontiers Media S.A.Frontiers in Public Health2296-25652024-01-011210.3389/fpubh.2024.12771131277113Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trialsWenting Cai0Wenting Cai1Ruobin Zhang2Ruobin Zhang3Yao Yao4Qiuhui Wu5Jinping Zhang6Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaDepartment of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaObjectiveTo systematically evaluate the efficacy and safety of a new hypoglycemic drug, tirzepatide, for treating obesity based on indicators such as BMI, waist circumference, and body weight.MethodsA search formula was written using search terms such as “tirzepatide,” “overweight,” and “obesity.” A comprehensive search was conducted on databases such as PubMed, Cochrane Library, Embase, and Web of Science using a computer. Random controlled trial (RCT) literature was selected based on inclusion and exclusion criteria. After extracting the data, literature bias risk assessment and meta-analysis were conducted using RevMan 5.4 software. The search deadline is from the establishment of each database to May 2023.ResultsA total of 12 randomized controlled trials were included, with a total of 11,758 patients. Meta analysis results showed that compared with the glucagon like peptide-1 receptor agonist (GLP-1 RAs), placebo and insulin groups, tirzepatide could significantly reduce the BMI (body mass index) of patients [MD = −1.71, 95% CI (−2.46, −0.95), p < 0.00001], [MD = −3.99, 95% CI (−3.69, −2.45), p < 0.00001], [MD = −4.02, 95% CI (−4.72, −3.31), p < 00.00001]. In terms of decreasing waist circumference, tirzepatide has a more significant advantage [MD = −4.08, 95% CI (−5.77, −2.39), p < 0.00001], [MD = −7.71, 95% CI (−10.17, −5.25), p < 0.00001], [MD = −9.15, 95% CI (−10.02, −8.29), p < 0.00001]. In the analysis of body weight, tirzepatide showed a more significant reduction effect compared to the control group [MD = −5.65, 95% CI (−7.47, −3.82), p < 0.001], [MD = −10.06, 95% CI (−12.86, −7.25), p < 0.001], [MD = −10.63, 95% CI (−12.42, −8.84), p < 0.001]. In comparison with placebo, tirzepatide had a prominent advantage in weight loss ≥20% and ≥25% [RR = 30.43, 95% CI (19.56, 47.33), p < 0.00001], [RR = 37.25, 95% CI (26.03, 53.30), p < 0.00001]. Subgroup analysis showed a dose-dependent therapeutic effect. In terms of safety, compared with the placebo and insulin groups, the incidence of gastrointestinal adverse reactions was markedly higher in the tirzepatide group, slightly higher to the GLP-1 RAs group. The hypoglycemic (<70 mg/dL) risk of tirzepatide was slightly higher to that of placebo and GLP-1 RAs, but significantly lower than that of the insulin group [RR = 0.46, 95% CI (0.36, 0.58), p < 0.001]. The incidence of other adverse events, including pancreatitis, cholecystitis, major adverse cardiovascular events-4, hypersensitivity reactions, and neoplasms did not show significant statistical differences compared to the control group (p > 0.05).ConclusionTirzepatide, as a weight loss drug, significantly reduces BMI, waist circumference and body weight while gastrointestinal adverse reactions need to be vigilant. Overall, its efficacy is significant and its safety is high.https://www.frontiersin.org/articles/10.3389/fpubh.2024.1277113/fulloverweightobesityBMIwaist circumferencetirzepatide |
| spellingShingle | Wenting Cai Wenting Cai Ruobin Zhang Ruobin Zhang Yao Yao Qiuhui Wu Jinping Zhang Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials Frontiers in Public Health overweight obesity BMI waist circumference tirzepatide |
| title | Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials |
| title_full | Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials |
| title_short | Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials |
| title_sort | tirzepatide as a novel effective and safe strategy for treating obesity a systematic review and meta analysis of randomized controlled trials |
| topic | overweight obesity BMI waist circumference tirzepatide |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2024.1277113/full |
| work_keys_str_mv | AT wentingcai tirzepatideasanoveleffectiveandsafestrategyfortreatingobesityasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT wentingcai tirzepatideasanoveleffectiveandsafestrategyfortreatingobesityasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT ruobinzhang tirzepatideasanoveleffectiveandsafestrategyfortreatingobesityasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT ruobinzhang tirzepatideasanoveleffectiveandsafestrategyfortreatingobesityasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yaoyao tirzepatideasanoveleffectiveandsafestrategyfortreatingobesityasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT qiuhuiwu tirzepatideasanoveleffectiveandsafestrategyfortreatingobesityasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jinpingzhang tirzepatideasanoveleffectiveandsafestrategyfortreatingobesityasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |